Technology
An injection pen is a spring, a screw, a moulded body and a glass cartridge, assembled to tolerances that let an untrained person deliver an accurate dose in a few seconds. It is a mechanical manufacturing problem wearing a pharmaceutical filing, and it is the part of the chain that most recently ran out.
In one sentence
An injection device is the mechanical assembly built around a drug container — a pen, autoinjector, safety syringe or on-body injector — moulded and assembled on dedicated lines and approved together with the medicine as a combination product.
The device exists because self-administration does. A patient injecting weekly at home cannot draw from a vial reliably, so the dose, the needle insertion, the delivery and the needle shielding are engineered into a disposable object. The design work is mechanical and human: spring force, dose-setting feedback, the audible click that tells someone the injection has finished.
Manufacturing is high-volume precision moulding and automated assembly with vision inspection, at units per year measured in the hundreds of millions for a successful product. Each line is built around specific tooling for a specific device and validated for a specific medicine, and that combination is why capacity could not be redirected during the shortages of recent years even where lines existed.
The device is assessed with the drug: the delivery mechanism, the container closure and evidence from human factors studies that patients can use it correctly, alongside the ordinary pharmaceutical dossier. Design changes therefore carry regulatory consequences, which is why device design freezes early and why a shortage cannot be met by a slightly different pen.
Tooling has lead times, the assembly line is bespoke, and validation runs long before approval for the first product filled on it. That sequence is measured in years and capital cannot compress it much, which is the mechanism behind supply of a medicine lagging demand while drug substance sat in storage.
Higher-volume and higher-viscosity biologic doses are pushing towards on-body injectors that deliver over minutes rather than seconds, which adds adhesives, electronics and a battery to what was a purely mechanical object. Connected pens that record doses add a data and software burden on top of a device filing.
2 of these are marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
The drug-contacting container inside the device is converted glass, qualified with the formulation before the device is designed around it.
Pharmaceutical glassThe moving seal and the needle cover are moulded elastomer, and their friction behaviour is what makes the device usable or not.
Elastomer componentsA pen is assessed as drug, container and device together, including whether patients can use it, which is much of why device capacity took so long to approve.
Regulatory approvalAssembly runs on dedicated validated lines built around specific tooling, which is multi-year capital rather than something bought in when demand arrives.
Other pages in this map that name Injection devices as something they cannot do without.
What each company supplies at this step, and — where a public figure exists — its share of this specific market — with what that share measures, the period it covers and who published it. Some rows also show the company’s own reported revenue for the segment covering this step, which is a different thing: it says how much this business matters to that company, not how much of the market it holds. Not a ranking and not a recommendation.
Supplies prefilled syringe systems, safety devices and the needles inside most of them.
Designs and assembles devices and also builds the assembly and inspection equipment other companies use.
Develops and assembles pens and autoinjectors as a platform other companies put their medicine into.
Assembles autoinjectors at very high volume for biologic products, largely from Taiwan and Switzerland.
Supplies injection and nasal delivery devices alongside the closures they are built with.
Supplies self-injection platforms including on-body delivery, from the same group that makes the seals.
Supplies pen injectors and safety devices, largely to companies that do not want a bespoke platform.
Assembles devices around the cartridges and syringes it converts, moving up from the container.
Whether device assembly capacity catches up with demand for self-administered injectables.
Whether on-body injectors take share as biologic dose volumes rise.
Whether connected devices add a data and regulatory burden that slows design cycles.
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer